δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches

34Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Mutations in the δ-sarcoglycan gene cause limb-girdle muscular dystrophy 2F (LGMD2F), an autosomal recessive disease that causes progressive weakness and wasting of the proximal limb muscles and often has cardiac involvement. Here we review the clinical implications of LGMD2F and discuss the current understanding of the putative mechanisms underlying its pathogenesis. Preclinical research has benefited enormously from various animal models of δ-sarcoglycan deficiency, which have helped researchers to explore therapeutic approaches for both muscular dystrophy and cardiomyopathy. © 2011 Blain and Straub; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Blain, A. M., & Straub, V. W. (2011, March 17). δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches. Skeletal Muscle. https://doi.org/10.1186/2044-5040-1-13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free